Noridian Issues Draft LCD for GenomeDx Prostate Biopsy Genomic Classifier

GenomeDx Biosciences announced today that Medicare administrative contractor Noridian GBA has issued a draft local coverage determination for use of the firm’s Decipher Prostate Biopsy genomic classifier in patients with very low and low-risk prostate cancer as defined by National Comprehensive Cancer Network guidelines.

Source: https://www.genomeweb.com/regulatory-news/noridian-issues-draft-lcd-genomedx-prostate-biopsy-genomic-classifier